ArticleScientific reports2017
Real-time imaging of intestinal bacterial β-glucuronidase activity by hydrolysis of a fluorescent probe.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Ingestible probes for breath-based monitoring of drug-metabolizing activity from the microbiome.Science advances · 2026Article
- Three bioactive compounds from Huangqin decoction ameliorate Irinotecan-induced diarrhea via dual-targeting of Escherichia coli and bacterial β-glucuronidase.Cell biology and toxicology · 2024Article
- Effect of Chromium Nanoparticles and Switching from a High-Fat to a Low-Fat Diet on the Cecal Microenvironment in Obese Rats.Nutrients · 2023Article
- Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model.British journal of pharmacology · 2023Article
- Gastrointestinal tract and neuroendocrine system responses of young turkeys to the early administration of antibiotics or feeding a diet containing a coccidiostat.Poultry science · 2022Article
- Pharmacological hypothesis: A recombinant probiotic for taming bacterial β-glucuronidase in drug-induced enteropathy.Pharmacology research & perspectives · 2022Article
- Recent advances of sensing strategies for the detection of β-glucuronidase activity.Analytical and bioanalytical chemistry · 2022Review
- Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan.Current drug metabolism · 2022Article
- Differential effects ofFrontiers in endocrinology · 2022Article
- Advances in activity-based diagnostics for infectious disease and microbiome health.Current opinion in biomedical engineering · 2021Article
- Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase.Frontiers in pharmacology · 2021Article
- The Role of Gut Microbial β-Glucuronidase in Estrogen Reactivation and Breast Cancer.Frontiers in cell and developmental biology · 2021Review
- Light-Emitting Probes for Labeling Peptides.Cell reports. Physical science · 2020Article
- Recent progress in the imaging detection of enzyme activitiesRSC advances · 2019Review
- Vancomycin relieves mycophenolate mofetil-induced gastrointestinal toxicity by eliminating gut bacterial β-glucuronidase activity.Science advances · 2019Article
- EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR.International journal of molecular medicine · 2019Article
- Sex, gut microbiome, and cardiovascular disease risk.Biology of sex differences · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal bacterial β-glucuronidase (βG) hydrolyzes glucuronidated metabolites to their toxic form in intestines, resulting in intestinal damage. The development of a method to inhibit βG is thus important but has been limited by the difficulty of directly assessing enzyme activity in live animals. Here, we utilized a fluorescent probe, fluorescein di-β-D-glucuronide (FDGlcU), to non-invasively image the intestinal bacterial βG activity in nude mice. In vitro cell-based assays showed that the detection limit is 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.